 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provided an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. This update follows a recent U.S. regulatory development for Fabry disease therapies, as well as AVROBIOs receipt of minutes from the companys Type B End-of-Phase 1 meeting with the U.S 